ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 04/08/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) InvestigationBusiness Wire • 04/04/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the FirmBusiness Wire • 04/04/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the FirmBusiness Wire • 04/03/23
Ascendis Stock Plunges As FDA Identifies Deficiencies In Company's New Drug ApplicationInvestors Business Daily • 04/03/23
ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASNDBusiness Wire • 04/03/23
Ascendis Pharma's Initial Dose Escalation Results from the Ongoing Phase 1/2 Trial of TransCon™ IL-2 β/γ Accepted for Online Publication at ASCO 2023GlobeNewsWire • 04/03/23
Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/10/23
Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16GlobeNewsWire • 02/07/23
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/23
Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with HypoparathyroidismGlobeNewsWire • 12/05/22
Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/22
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with HypoparathyroidismGlobeNewsWire • 11/14/22
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma's Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 YearsGlobeNewsWire • 11/13/22
Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022GlobeNewsWire • 11/11/22